Abstract

U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)

Author(s):

Issue: Nov/Dec 2016 - Volume 20, Number 6

Page(s): 457-458

Download in electronic PDF format for $75
  • U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) Page 1
  • U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) Page 2

Abstract

Related Keywords

  • U.S. Food and Drug Administration
  • pharmacy regulation
  • FDA
  • Federal Food, Drug, and Cosmetic Act
  • do not compound
  • negative list
  • FD&C Act
  • Section 503A

Related Categories

  • INFUSION
  • LEGAL
  • SUPPORT
  • QUALITY CONTROL
  • DISCONTINUED FORMULATIONS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Nov/Dec 2016
Pg. 457-458
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
Author(s):
Jul/Aug 2016
Pg. 351
View Sample
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Author(s): Allen Loyd V Jr
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Author(s): Allen Loyd V Jr
Nov/Dec 2016
Pg. 477-479
The "Lists": What Do They Mean?
Author(s): Voliva John
Jul/Aug 2015
Pg. 303-305
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Author(s): Miller David G
Sep/Oct 2021
Pg. 358-362
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Author(s): Cabaleiro Joe
Jan/Feb 2005
Pg. 44-46
The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List")
Author(s): Allen Loyd V Jr, Ashworth Lisa D
Mar/Apr 2017
Pg. 95-102
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Author(s): Yoch Doug
Jul/Aug 2020
Pg. 296-297
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Author(s): Brunner Scott
Jul/Aug 2015
Pg. 311-313
Basics of Compounding: The "Negative" List
Author(s): Allen Loyd V
Sep/Oct 2014
Pg. 379-380
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Author(s): Blankenship Cynthia E
May/Jun 2014
Pg. 208
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Author(s): Miller David G
Jan/Feb 2023
Pg. 22-23
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Author(s): Brunner Scott
Sep/Oct 2015
Pg. 389-390
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Author(s): Allen Loyd V Jr
Jan/Feb 2019
Pg. 32-33
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Jan/Feb 2015
Pg. 57-58
Basics of Compounding: The Revised "Not to Compound List"
Author(s): Allen Loyd V Jr
Mar/Apr 2022
Pg. 100-109
Allowing Compounding Pharmacies to Address Drug Shortages
Author(s): Broughel James
Mar/Apr 2015
Pg. 104-106
Standing Together Fixing the Drug Quality and Security Act
Author(s): Miller David G
Jul/Aug 2007
Pg. 326-327
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration
Author(s): Kupiec Tom, Kemp Jesse